• news.cision.com/
  • Intervacc/
  • Intervacc AB and the Swedish University of Agricultural Sciences, SLU, sign a multi-year contract for the development of innovative animal health vaccines

Intervacc AB and the Swedish University of Agricultural Sciences, SLU, sign a multi-year contract for the development of innovative animal health vaccines

Report this content

Intervacc AB and the Swedish University of Agricultural Sciences, SLU, have signed a multi-year contract for the development of a new generation of animal health vaccines using recombinant proteins. The contract is a continuation and expansion of the very successful collaboration between SLU, Karolinska Institutet (KI) and Intervacc that has led to the development of Strangvac, an innovative new vaccine against strangles, a highly contagious and serious infection in horses. The agreement includes the continued development of two other vaccine projects with great potential to bring modern vaccine technology into the animal health sector.

“Intervacc is very satisfied with the results that our research teams at SLU and KI have achieved together and we are confident that Strangvac is just the first of a series of recombinant based vaccines that will emerge from these ongoing collaborations. We are at the forefront of some very interesting animal health vaccine technologies and we are excited about the ability to utilize this knowledge within vaccinology to bring new animal health vaccines to the market" – says Andreas Andersson, CEO Intervacc AB

Intervacc’s research pipeline, in addition to Strangvac, includes two vaccine projects. One project against infections in piglets caused by the bacterium Streptococcus suis and a second project against infections caused by the bacterium, Staphylococcus aureus, which results in mastitis, a hard to treat disease of the udder in dairy cows.

Streptococcus suis causes severe infections in some pig herds with devastating results for the pig industry. There are almost one billion pigs worldwide and the need for a working vaccine is in great demand. Vaccine development is also a crucial tool for reducing the widespread resistance of antibiotics a global threat of great concern.

SLU is a world class research focused university and Sweden's leading agricultural institution. It includes an animal hospital and has facilities for animal and plant research as well as several other disciplines within the natural and social sciences. It offers 40-degree programmes and has over 3,500 students as well as 550 doctoral students.

“I’m very pleased with the cooperation with Intervacc and we are excited to continue the work together with the development team. Together we are a leader in developing vaccines using fusions of recombinant proteins, and we believe firmly that we are only in the beginning of this expanding field. This agreement confirms Intervacc and SLU’s long-term commitment to the project.” – says professor Bengt Guss, project leader at SLU.

Intervacc Chief Scientific Officer, professor Jan-Ingmar Flock, summarizes “We are a unified research team with unique expertise and ability to deliver extraordinary results. It’s a great collaboration and this long-term agreement with SLU enables Intervacc to move forward with an increasingly strong pipeline of research and development opportunities for an expanded set of animal health vaccines.” 

For more information please contact:                     

Andreas Andersson, CEO,
E-mail: andreas.andersson@intervacc.com, Phone: +46-8-120 10 601
Jan-Ingmar Flock, CSO - Chief Scientific Officer,
E-mail: jan-ingmar.flock@intervacc.com, Phone: +46-8-120 10 602

This information is information that Intervacc AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on June 11, 2019.

About Intervacc

Intervacc AB (publ) is a company within the Biotechnology sector. The Company´s main area is to develop modern sub-unit vaccines against economically important bacterial infections, mainly within animal health. The company´s vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the company´s research and development work. The Intervacc share has been listed on the NASDAQ First North market since April 2017 with Eminova Fondkommission AB, info@eminova.se, +46 (0)8–684 211 00 as Certified Adviser.

About SLU the Swedish University of Agricultural Sciences

SLU, the Swedish University of Agricultural Sciences, is a world-class international university with research, education and environmental assessment within the sciences for sustainable life. Its principal sites are in Alnarp, Umeå and Uppsala, but activities are also conducted at research stations, experimental parks and educational establishments throughout Sweden. We bring together people who have different perspectives, but they all have one and the same goal: to create the best conditions for a sustainable, thriving and better world. Please visit the website http://www.slu.se/ for more information.

About Strangvac

Strangvac a modern vaccine against Strangles, a highly contagious and serious infection in horses caused by the bacterium Streptococcus equi. Strangvac, that consists of only soluble recombinant proteins, is injected intramuscularly and totally devoid of any living infectious agent. This results in a well-tolerated vaccine with excellent safety profile, as expected of a modern vaccine. Intervacc plans to submit the dossier for Strangvac to the European Medicines Agency by the end of 2019.

Contact information for Certified Adviser

Eminova Fondkommission AB
E-mail: info@eminova.se, Phone: +46 (0)8 – 684 211 00